Our Bureau

Hyderabad, June 11 Jupiter Biosciences Ltd (JBL), the Hyderabad-based mid-sized pharma company, feels the strategic buy of Ranbaxy’s promoter’s stake by Daiichi Sankyo would give a push to its own efforts to enter the Japanese market with its peptide offerings.

Jupiter Biosciences had divested 14.9 per cent stake to Ranbaxy last year and entered into a 10 year marketing tie-up for its pipeline of peptide based products, said Mr Venkat Kalavakolanu, its Chairman and Managing Director.

“For us it will be a good association, since we are trying to enter the tough, regulated Japanese market. The development would be a natural fit for our peptides and chiral intermediates,” he told Business Line.

Ranbaxy had picked up stake in the company with an eye on the latter’s peptide pipeline, which it expected to yield good returns after 4-5 years. Daiichi is strong both in innovation and generics and hence, for a research-driven company like ours, it augurs well, he said.

“For the next one year we will deal with Ranbaxy. Normally till the merger or acquisition process is completed not much change in relationships are expected,” Mr Venkat said.

© Copyright 2000 - 2009 The Hindu Business Line